Application for registration of new lung cancer drug toluenesulfonamide production of HongRi Pharmaceutical Co., Ltd. accepted

In the afternoon of May 19, HongRi pharmaceutical announced that the application for production registration of p-toluenesulfonamide (hereinafter referred to as "PTS") jointly declared by the company and its subsidiary Tianjin hongrijiandakang Pharmaceutical Technology Co., Ltd was officially accepted by the drug review center of the State Food and Drug Administration on May 15, 2014 The application scope of the third phase clinical trial of this product is central lung cancer with severe airway obstruction According to the relevant provisions of the measures for the administration of drug registration of the people's Republic of China, after the PTS production registration is accepted, the production approval can only be obtained after passing the technical review and approval procedures The results and time of interim review and approval are uncertain to some extent, and the final approval or not shall be determined after the review of relevant national departments The application for production registration of the product is accepted, which will not affect the company's recent performance.